Triple
T10292303
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | human adenovirus serotype 26 |
E241391
|
entity |
| Predicate | vectorBackboneUsedBy |
P2565
|
FINISHED |
| Object | Janssen COVID-19 Vaccine |
E49854
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Janssen COVID-19 Vaccine | Statement: [human adenovirus serotype 26, vectorBackboneUsedBy, Janssen COVID-19 Vaccine]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Janssen COVID-19 Vaccine Context triple: [human adenovirus serotype 26, vectorBackboneUsedBy, Janssen COVID-19 Vaccine]
-
A.
Janssen COVID-19 Vaccine
chosen
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
B.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
C.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
E.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: vectorBackboneUsedBy Context triple: [human adenovirus serotype 26, vectorBackboneUsedBy, Janssen COVID-19 Vaccine]
-
A.
isBackboneOf
chosen
Indicates that one entity forms the main supporting structure or central framework upon which another entity fundamentally depends.
-
B.
backedFor
Indicates that one entity provides support, endorsement, or backing for another entity, often in a financial, political, or strategic context.
-
C.
areUsedBy
Indicates that certain entities serve as tools, resources, or means that are utilized or employed by other entities.
-
D.
vector
Indicates that one entity is a vector associated with, representing, or characterizing another entity (such as a quantity with magnitude and direction, or a carrier/representative of something).
-
E.
supportsBackplane
Indicates that one entity provides compatibility with or the capability to operate using another entity’s backplane infrastructure.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d7500fdd1c81909395469afb346f8b |
completed | April 9, 2026, 7:06 a.m. |
| PD | Predicate disambiguation | batch_69d4d1f35e548190be3b4d92d65d2d20 |
completed | April 7, 2026, 9:44 a.m. |
Created at: April 6, 2026, 11:42 a.m.